

C. McCLAIN HADDOW
2921 MOTHER WELL COURT
OAK HILL, VIRGINIA 20171
TELEPHONE: (703) 471-5210

SECRETARY OF THE SENATE
00 OCT 13 PM 2:52

October 11, 2000

The Honorable Jeff Trandahl
Clerk, U.S. House of Representatives
c/o Legislative Resource Center
B-106 Cannon House Office Building
Washington, D.C. 20515-6612

Dear Mr. Trandahl:

In your notice of October 4, 2000 regarding "First Notice of Non-Receipt" you indicate that an appropriate filing and a written explanation of any delinquency should be made for the lobby report covering the period of January 1, 2000 to June 30, 2000.

Attached you will find a copy of the document that I thought had been mailed to the appropriate offices on or about August 15, 2000.

My apologies for whatever error resulted in your non-receipt of these documents.

Sincerely,



C. McClain Haddow

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

00 OCT 13 PM 2: 52

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name C. McClain Haddow			
2. Address <input type="checkbox"/> Check if different than previously reported 2921 Mother Well Court Herndon VA 20171			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name C. McClain Haddow	Telephone 703-471-5210	E-mail (optional) machaddow@erols.com	5. Senate ID # 17248-12
7. Client Name <input type="checkbox"/> Self Mylan Laboratories			6. House ID # 30054000

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$20,000.00</u> Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code

Signature

C. McClain Haddow

Date 8/15/2000

Printed Name and Title

C. McClain Haddow - President

Page 1 of 2

Registrant Name: C. McClain Haddow

Client Name: Mylan Laboratories

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

- S. 1172, Drug Patent Term Restoration Review Procedure Act of 1999, Generic drug access
- H.R. 3240, Drug Import Fairness Act of 2000, Generic drug access
- S. 1798, American Inventors Protection Act of 1999, Generic drug access
- H.R. 4683, International Patent Act of 2000, Generic drug access
- H.R. 4770, Medicare Guaranteed and Defined Rx Benefit and Health Provide Relief Act of 2000, Generic drug access
- S. 2753, Medicare Expansion of Needed Drugs Act of 2000, Generic drug access
- H.R. 4369, Veterans' Health Care Improvement and Prescription Drug Cost Relief Act of 2000, Generic drug access
- S. 2087, Military Health Care Improvements Act of 2000, Generic drug access
- S. 2504, Generic Pharmaceutical Access and Choice for Consumers Act of 2000, Generic drug access

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Haddow, C. McClain</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature C. McClain Haddow Date 8/15/2000

Printed Name and Title C. McClain Haddow - President Page 2 of 2